



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/12, C07K 14/47, 16/18, G01N 33/566, C12Q 1/68, C12N 15/11, 15/62, A01K 67/027, A61K 38/00</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/58473</b> (43) International Publication Date: <b>5 October 2000 (05.10.00)</b>																
(21) International Application Number: <b>PCT/US00/08621</b> (22) International Filing Date: <b>31 March 2000 (31.03.00)</b> (30) Priority Data: <table border="0"> <tr> <td>60/127,607</td> <td>31 March 1999 (31.03.99)</td> <td>US</td> </tr> <tr> <td>60/127,636</td> <td>2 April 1999 (02.04.99)</td> <td>US</td> </tr> <tr> <td>60/127,728</td> <td>5 April 1999 (05.04.99)</td> <td>US</td> </tr> <tr> <td>09/540,763</td> <td>30 March 2000 (30.03.00)</td> <td>US</td> </tr> </table>		60/127,607	31 March 1999 (31.03.99)	US	60/127,636	2 April 1999 (02.04.99)	US	60/127,728	5 April 1999 (05.04.99)	US	09/540,763	30 March 2000 (30.03.00)	US	(72) Inventors; and (75) Inventors/Applicants (for US only): SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US). LEACH, Martin [GB/US]; 884 School Street, Webster, MA 01570 (US). (74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).					
60/127,607	31 March 1999 (31.03.99)	US																	
60/127,636	2 April 1999 (02.04.99)	US																	
60/127,728	5 April 1999 (05.04.99)	US																	
09/540,763	30 March 2000 (30.03.00)	US																	
(63) Related by Continuation (CON) or Continuation-In-Part (CIP) to Earlier Applications <table border="0"> <tr> <td>US</td> <td>60/127,607 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>31 March 1999 (31.03.99)</td> </tr> <tr> <td>US</td> <td>60/127,636 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>2 April 1999 (02.04.99)</td> </tr> <tr> <td>US</td> <td>60/127,728 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>5 April 1999 (05.04.99)</td> </tr> <tr> <td>US</td> <td>09/540,763 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>30 March 2000 (30.03.00)</td> </tr> </table>		US	60/127,607 (CIP)	Filed on	31 March 1999 (31.03.99)	US	60/127,636 (CIP)	Filed on	2 April 1999 (02.04.99)	US	60/127,728 (CIP)	Filed on	5 April 1999 (05.04.99)	US	09/540,763 (CIP)	Filed on	30 March 2000 (30.03.00)	(71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US). Published Without international search report and to be republished upon receipt of that report.	
US	60/127,607 (CIP)																		
Filed on	31 March 1999 (31.03.99)																		
US	60/127,636 (CIP)																		
Filed on	2 April 1999 (02.04.99)																		
US	60/127,728 (CIP)																		
Filed on	5 April 1999 (05.04.99)																		
US	09/540,763 (CIP)																		
Filed on	30 March 2000 (30.03.00)																		
(54) Title: <b>NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES: "ORFX"</b>																			
(57) Abstract <p>The present invention provides open reading frames ORFX, encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.</p>																			

```

          115          120          125
Ser Val Ala Asn Lys His Gly His Tyr Pro Asn Thr Ile Ala Glu Lys
130          135          140
His Gly Phe Arg Asp Leu Arg Gln Phe Ile Asp Glu Tyr Val Glu Thr
145          150          155
Val Asp Met Leu Lys Ser His Ile Lys Glu Glu Leu Met His Gly Glu
          165          170          175
Glu Ala Asp Ala Val Tyr Glu Ser Met Ala His Leu Ser Thr Asp Leu
180          185          190
Leu Met Lys Cys Ser Leu Asn Pro Gly Cys Asp Glu Asp Leu Tyr Glu
195          200          205
Ser Met Ala Ala Phe Val Pro Ala Ala Thr Glu Asp Leu Tyr Val Glu
210          215          220
Met Leu Gln Ala Ser Thr Ser Asn Pro Ile Pro Gly Asp Gly Phe Ser
225          230          235
Arg Ala Thr Lys Asp Ser Met Ile Arg Lys Phe Leu Glu Gly Asn Ser
          245          250          255
Met Gly Met Thr Asn Leu Glu Arg Asp Gln Cys His Leu Gly Gln Glu
260          265          270
Glu Asp Val Tyr His Thr Val Asp Asp Asp Glu Ala Phe Ser Val Asp
275          280          285
Leu Ala Ser Arg Pro Pro Val Pro Val Pro Arg Pro Glu Thr Thr Ala
290          295          300
Pro Gly Ala His Gln Leu Pro Asp Asn Glu Pro Tyr Ile Phe Lys Gly
305          310          315          320
Lys Tyr Gly Arg Glu
          325

```

&lt;210&gt; 3727

&lt;211&gt; 630

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3727

```

cggattcgag tcatcaagaa gaaaaaggtc attatgaaga agcgggaagaa gctaactcta
60
actcgcccca cccactggt gactgccggg ccccttggtga ccccaactcc agcaggggacc
120
ctcgaccccg ctgagaaaca agaaacaggc tgtcctcctt tgggtctgga gtccttgcca
180
gtttcagata gcgggcttga ggcacccagc agccagtcct ttggtcttgg accacaccga
240
ggacggctca acattcagtc aggcctggag gacggcgatc tatatgatgg agcctgggtgt
300
gctgaggagc aggacgccga tccatggttt caggtggacg ctgggcaccc caccgcttc
360
tcgggtgtta tcacacaggg caggaactct gtctggaggt atgactgggt cacatcatc
420
aaggtccagt tcagcaatga cagtcggacc tggtagggaa gtaggaacca cagcagtggg
480
atggacgcag tatttcctgc caattcagac ccagaaactc cagtgtgaa cctcctgccg
540
gagccccagg tggcccgctt cattcgctg ctgccccaga cctggctcca gggaggcgcg
600

```

ccttgccctcc gggcagagat cctggcctgc  
630

<210> 3728  
<211> 210  
<212> PRT  
<213> Homo sapiens

<400> 3728  
Arg Ile Arg Val Ile Lys Lys Lys Lys Val Ile Met Lys Lys Arg Lys  
1 5 10 15  
Lys Leu Thr Leu Thr Arg Pro Thr Pro Leu Val Thr Ala Gly Pro Leu  
20 25 30  
Val Thr Pro Thr Pro Ala Gly Thr Leu Asp Pro Ala Glu Lys Gln Glu  
35 40 45  
Thr Gly Cys Pro Pro Leu Gly Leu Glu Ser Leu Arg Val Ser Asp Ser  
50 55 60  
Arg Leu Glu Ala Ser Ser Ser Gln Ser Phe Gly Leu Gly Pro His Arg  
65 70 75 80  
Gly Arg Leu Asn Ile Gln Ser Gly Leu Glu Asp Gly Asp Leu Tyr Asp  
85 90 95  
Gly Ala Trp Cys Ala Glu Glu Gln Asp Ala Asp Pro Trp Phe Gln Val  
100 105 110  
Asp Ala Gly His Pro Thr Arg Phe Ser Gly Val Ile Thr Gln Gly Arg  
115 120 125  
Asn Ser Val Trp Arg Tyr Asp Trp Val Thr Ser Tyr Lys Val Gln Phe  
130 135 140  
Ser Asn Asp Ser Arg Thr Trp Trp Gly Ser Arg Asn His Ser Ser Gly  
145 150 155 160  
Met Asp Ala Val Phe Pro Ala Asn Ser Asp Pro Glu Thr Pro Val Leu  
165 170 175  
Asn Leu Leu Pro Glu Pro Gln Val Ala Arg Phe Ile Arg Leu Leu Pro  
180 185 190  
Gln Thr Trp Leu Gln Gly Gly Ala Pro Cys Leu Arg Ala Glu Ile Leu  
195 200 205  
Ala Cys  
210

<210> 3729  
<211> 1552  
<212> DNA  
<213> Homo sapiens

<400> 3729  
naggaaacgc tttgtctgtc cygcaagccg acggcccgc gctggcctcc gtgacgcggg  
60  
cctcctccgc gcctcgccgc atggagtaga aagggaccgc ggaagccga aagcgaaggc  
120  
atcaagttat cagcagatgt caaaccattt gtccccagat ttgccgggct caatgtggca  
180  
tggttagagt cctcagaagc atgtgtcttc cccagctctg cagccacata ctatccgttt  
240  
gttcaggaac caccagtgc agagcagaaa atatatactg aagacatggc ctttggagct  
300

**What is claimed is:**

1. An isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is any integer 1-3161, or the complement thereof.
2. The isolated nucleic acid molecule of claim 1, said molecule hybridizing under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule comprising the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 $n$ , wherein  $n$  is any integer 1-3161, or the complement thereof.
3. The isolated nucleic acid molecule of claim 1, said molecule encoding a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 $n$ , wherein  $n$  is any integer 1-3161, or an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence selected from the group consisting of SEQ ID NO: 2 $n$ .
4. The isolated nucleic acid molecule of claim 1, wherein said molecule encodes a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 $n$ , wherein  $n$  is any integer 1-3161.
5. The isolated nucleic acid molecule of claim 1, wherein said molecule comprises the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is any integer 1-3161, or the complement thereof.
6. An oligonucleotide less than 100 nucleotides in length and comprising at least contiguous nucleotides selected from the group consisting of SEQ ID NO:2 $n$ -1, wherein  $n$  is any integer 1-3161, or the complement thereof.
7. A vector comprising the nucleic acid molecule of claim 1.

compound, and detecting said complex, if present, thereby identifying said polypeptide in said sample.

17. A method of detecting the presence of a nucleic acid molecule of claim 1 in a sample, the method comprising contacting the sample with a nucleic acid probe or primer that selectively binds to the nucleic acid molecule and determining whether the nucleic acid probe or primer bound to the nucleic acid molecule of claim 1 is present in the sample.

18. A method for modulating the activity of the polypeptide of claim 10, the method comprising contacting a cell sample comprising the polypeptide of claim 10 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

19. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a ORFX-associated disorder, wherein said therapeutic is selected from the group consisting of:

- a) the nucleic acid of claim 1;
- b) the polypeptide of claim 10; and
- c) the antibody of claim 12.

20. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) contacting a test compound with the polypeptide of claim 10; and
- b) determining if said test compound binds to said polypeptide,

wherein binding of said test compound to said polypeptide indicates the test compound is a modulator of activity or of latency or predisposition to an ORFX-associated disorder.

21. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) administering a test compound to a test subject at an increased risk ORFX-associated disorder, wherein said test subject recombinantly expresses a polypeptide encoded by the nucleotide of claim 1;

wherein an alteration in the level of the nucleic acid in step (a) as compared to the control sample indicates the presence of or predisposition to said disease in said subject.

26. The method of claim 25, wherein said subject is a human.

27. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject polypeptide of claim 10 in an amount sufficient to alleviate or prevent said pathological condition.

28. The method of claim 27, wherein said subject is a human.

29. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject nucleic acid molecule of claim 1 in an amount sufficient to alleviate or prevent said pathological condition.

30. The method of claim 29, wherein said subject is a human.

31. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject antibody of claim 12 in an amount sufficient to alleviate or prevent said pathological condition.

32. The method of claim 31, wherein said subject is a human.